We are live on ! Find out more
BRA

Bender Robert & Associates Portfolio holdings

AUM $417M
1-Year Est. Return 25.02%
This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+25.02%
3 Year Est. Return
+98.12%
5 Year Est. Return
+139.29%
10 Year Est. Return
+812.75%
AUM
$267M
AUM Growth
+$9.19M
Cap. Flow
-$4.55M
Cap. Flow %
-1.7%
Top 10 Hldgs %
67.14%
Holding
56
New
2
Increased
4
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$226K
2
AEP icon
American Electric Power
AEP
+$196K
3
PANW icon
Palo Alto Networks
PANW
+$88.3K
4
LLY icon
Eli Lilly
LLY
+$26.6K
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$1.52K

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$864K
2
VMW
VMware, Inc
VMW
+$549K
3
URGN icon
UroGen Pharma
URGN
+$342K
4
AAPL icon
Apple
AAPL
+$324K
5
ISRG icon
Intuitive Surgical
ISRG
+$297K

Sector Composition

Rank Sector Weight
1 Technology 35.74%
2 Consumer Discretionary 28.37%
3 Healthcare 24.05%
4 Communication Services 8.46%
5 Utilities 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VMW
26
DELISTED
VMware, Inc
VMW
$2.03M 0.76%
16,555
-4,762
-22% -$549K
BMY icon
27
Bristol-Myers Squibb
BMY
$128B
$2.01M 0.75%
27,947
– –
AMD icon
28
Advanced Micro Devices
AMD
$807B
$1.91M 0.72%
29,560
-620
-2% -$40.9K
PFE icon
29
Pfizer
PFE
$141B
$1.06M 0.4%
20,630
– –
JNJ icon
30
Johnson & Johnson
JNJ
$641B
$971K 0.36%
5,497
-10
-0.2% -$1.73K
ABT icon
31
Abbott
ABT
$182B
$958K 0.36%
8,726
-260
-3% -$26.9K
MRK icon
32
Merck
MRK
$323B
$953K 0.36%
8,592
– –
CTSH icon
33
Cognizant
CTSH
$22.3B
$860K 0.32%
15,044
-667
-4% -$39.1K
COST icon
34
Costco
COST
$422B
$858K 0.32%
1,880
-3
-0.2% -$1.47K
NSC icon
35
Norfolk Southern
NSC
$77.1B
$850K 0.32%
3,451
-90
-3% -$21.3K
PAYX icon
36
Paychex
PAYX
$41.1B
$790K 0.3%
6,835
-315
-4% -$36.9K
DE icon
37
Deere & Co
DE
$169B
$669K 0.25%
1,561
– –
BA icon
38
Boeing
BA
$167B
$560K 0.21%
2,940
– –
JPM icon
39
JPMorgan Chase
JPM
$947B
$554K 0.21%
4,134
– –
NUE icon
40
Nucor
NUE
$56.4B
$545K 0.2%
4,135
-55
-1% -$7.47K
PANW icon
41
Palo Alto Networks
PANW
$259B
$497K 0.19%
7,130
+1,100
+18% +$88.3K
CAT icon
42
Caterpillar
CAT
$402B
$387K 0.14%
1,617
– –
TGT icon
43
Target
TGT
$63.7B
$310K 0.12%
2,080
– –
DUK icon
44
Duke Energy
DUK
$100B
$270K 0.1%
2,626
– –
TROW icon
45
T. Rowe Price
TROW
$25.5B
$233K 0.09%
2,135
– –
V icon
46
Visa
V
$689B
$233K 0.09%
+1,120
New +$226K
AEP icon
47
American Electric Power
AEP
$72.7B
$204K 0.08%
+2,150
New +$196K
TOON icon
48
Kartoon Studios
TOON
$34.9M
$23.3K 0.01%
5,000
– –
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.43B
– –
-68,600
Closed -$864K
EOLS icon
50
Evolus
EOLS
$407M
– –
-25,070
Closed -$202K
1
2
3

Similar funds

AWCI
Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return
ACM
Alight Capital Management New York $417M AUM 98.18% 1-Year Est. Return
PA
PSI Advisors Tampa, Florida $418M AUM 15.55% 1-Year Est. Return
CEI
Clark Estates Inc New York $416M AUM 6.04% 1-Year Est. Return
MCM
Millstreet Capital Management Boston, Massachusetts $418M AUM 80.77% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SCP
Stevens Capital Partners Omaha, Nebraska $416M AUM 18.93% 1-Year Est. Return
VM
Venator Management Pittsburgh, Pennsylvania $416M AUM 16.01% 1-Year Est. Return

Bender Robert & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Bender Robert & Associates held 56 positions worth $267M, up 3.6% from $258M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Bender Robert & Associates's Q4 2022 filing shows 2 new, 4 increased, 30 reduced and 8 closed positions. Its largest new stake was Visa: 1,120 shares worth $233K. The largest sale was BioCryst Pharmaceuticals, an estimated $864K.

By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 37% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Bender Robert & Associates's largest Q4 2022 buy was Visa: 1,120 shares worth $233K.
  • Bender Robert & Associates added most to Palo Alto Networks in Q4 2022, an estimated $88.3K increase.
  • Bender Robert & Associates's biggest Q4 2022 reduction was VMware, Inc, cutting an estimated $549K.
  • Bender Robert & Associates fully exited BioCryst Pharmaceuticals in Q4 2022, selling an estimated $864K.
  • Bender Robert & Associates's ten largest holdings make up 67% of its $267M portfolio in Q4 2022.
  • Bender Robert & Associates opened 2 new positions and closed 8 in Q4 2022.
  • Bender Robert & Associates's portfolio value rose 3.6% quarter-over-quarter to $267M.

Based on Bender Robert & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.